How effective are ketamine or esketamine in treatment-resistant depression?

INTRODUCTION: Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span of 24-hours. Recently, the FDA approved esketa...

Descripción completa

Detalles Bibliográficos
Autores principales: Veluri, N., Mansuri, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471430/
http://dx.doi.org/10.1192/j.eurpsy.2021.886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471430/
http://dx.doi.org/10.1192/j.eurpsy.2021.886

Ejemplares similares